<DOC>
	<DOC>NCT00162799</DOC>
	<brief_summary>To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.</brief_summary>
	<brief_title>Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity</brief_title>
	<detailed_description>Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled. Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days Washout period: 30 days</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Triflusal</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<criteria>Ages 35 to 60 years old</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>insulin resistance and inflamation</keyword>
	<keyword>insulin sensitibity</keyword>
	<keyword>obesity-induced insuline resistence</keyword>
	<keyword>obesity-diabetes link</keyword>
	<keyword>salicylate</keyword>
	<keyword>insulin resistance in obesity health adults</keyword>
</DOC>